Clinical trials: Bladder Neoplasm
Urinary Bladder Neoplasms
Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Urinary Bladder Neoplasms.
- Trial name
- IRE (NCT02430623)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Bladder Cancer
Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
This is a phase II study of Paclitaxel-binding albumin, Cisplatin as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder.
- Trial name
- NCT04060459
- Testing
- Paclitaxel-binding albumin
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Third Military Medical University
Bladder Neoplasm, Prostatic Neoplasms
Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block
Bladder irrigation with a 3 way foley catheter is an important component of post operative management of transurethral bladder surgeries. But it is associated with a high incidence of bladder discomfort.
- Trial name
- NCT05022160
- Testing
- pudendal nerve block
- Where
- Pakistan
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Armed Forces Hospital, Pakistan
Bladder Cancer
Genetic Susceptibility to Bladder Cancer
This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer.
- Trial name
- NCT00848289
- Testing
- Interviews
- Where
- 2 sites in United States
- Volunteers
- 6,086 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Spinal Anaesthesia, Bladder Tumor
A Retrospective Analysis of Spinal Anaesthesia for TURBT Procedures in Elderly Patients
The aim of the study was to evaluate the safety and effectiveness of spinal anesthesia among elderly patients The basic methods for diagnosis and management of bladder cancer include endoscopic procedures (cystoscopy…
- Conditions
- Spinal Anaesthesia, Bladder Tumor, Transurethral Resection
- Trial name
- NCT03221829
- Where
- Poland
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Healthy Volunteers
A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers
The primary objective of the study is to assess safety and tolerability following administration of single doses of APL-1202 (immediate release) IR tablets and APL-1501 extended release (ER) capsules in healthy participants.
- Trial name
- NCT06435039
- Testing
- APL-1202, APL-1501
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Pancreas Cancer, Hepatocellular Carcinoma
Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
The purpose of this clinical trial is to evaluate whether volatile organic compound (VOC) signatures detected in the breath of patients with cancer can serve as a potential screening tool for the early detection of cancer.
- Conditions
- Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer
- Trial name
- NCT07732686
- Testing
- Proton Transfer Reaction Mass Spectrometry Analysis
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Bladder Tumor
Assessment of the Uro-C Cystoscope for Use in Diagnostic Cystoscopy Procedures
This is a prospective, multicenter, single-arm, open-label clinical usability study in subjects who are candidates for office diagnostic cystoscopy.
- Trial name
- NCT03331705
- Testing
- Uro-C (Use of new cystoscope)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- UroSee Corporation
Bladder Cancer
UroX Biomarker Bladder Cancer Study
This is a prospective observational study looking at urine samples from participants under referral for a standard of care investigative cystoscopy and biopsy.
- Trial name
- NCT03973307
- Testing
- UroX bladder cancer biomarker test
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- East and North Hertfordshire NHS Trust
Bladder Cancer
A Diagnostic for the Early Detection of Bladder Cancer
To improve upon the non-invasive detection of bladder cancer by further validating a multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in voided urine samples of patients with a high risk of…
- Trial name
- NCT05347342
- Where
- 2 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Upper Urinary Tract Urothelial Carcinoma, Bladder Cancer
Single-Dose Intravesical Chemotherapy After Diagnostic URS
Study design This study is a Phase III, randomized, open-label, multi-center, global study to determine the efficacy of a single immediate intravesical chemotherapy instillation (SI) in the prophylaxis of intravesical recurrence…
- Trial name
- MINERVA (NCT05810623)
- Testing
- Intravesical Solution
- Where
- 2 sites in Austria
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- David D'Andrea
Invasive Bladder Cancer
HIPEC After Radical Cystectomy for High Risk Bladder Cancer
This is a non-randomized, non-blinded, pilot study administering hyperthermic intraperitoneal chemotherapy with Mitomycin-C in 10 men and women with muscle-invasive urothelial carcinoma of the bladder undergoing radical…
- Trial name
- NCT03514888
- Testing
- HIPEC
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Urinary Bladder Neoplasms
Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer
Gemcitabine and cisplatin represent the standard first-line chemotherapy in metastatic bladder carcinoma. This regimen has replaced in most centers the MVAC combination showing a similar efficacy but less toxicity.
- Trial name
- NCT00818350
- Testing
- SUNITINIB
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Campania Younger Oncologists Association
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Bladder Cancer
Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and…
- Trial name
- NCT01198808
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Superficial Bladder Cancer
Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer
This protocol is evaluating efficacy and toxicity of three sequential whole bladder photodynamic treatment with Photofrin and red laser light (630 nm) in the management of superficial bladder cancer (non-muscle invasive) in those…
- Trial name
- NCT00322699
- Testing
- Whole bladder laser light treatment as an alternative to radical cystectomy, Photofrin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- North Florida/South Georgia Veterans Health System
Muscle-invasive Bladder Urothelial Carcinoma
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
This is a prospective, open-label, single-center, single-arm clinical study. Plans to enroll 45 MIBC patients with clinical stage T2-T4aN0M0 and HER2-positive (IHC 1+/2+/3+) status.
- Trial name
- NCT07279597
- Testing
- RC48-ADC + Toripalimab
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Healthy Participants, Pelvic Neoplasms
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
This study will help to elucidate the treatment sites in the extremities and pelvis for which MR-guided HIFU heating is feasible, which has the potential to be beneficial for patients with conditions at those sites (soft tissue…
- Conditions
- Healthy Participants, Pelvic Neoplasms, Soft-tissue Sarcoma, Bladder Cancer
- Trial name
- NCT03007771
- Testing
- Magnetic Resonance-guided High-Intensity Focused Ultrasound
- Volunteers
- healthy volunteers welcome
- Sponsor
- Washington University School of Medicine